SenzaGen’s subsidiary receives strategically important order
SenzaGens’s subsidiary VitroScreen has received an order from an existing customer for non-animal efficacy testing. The order includes studies using the proprietary platform VitroScreenORA® and is carried out within the framework of the Group’s strategic initiative to scale the business through new innovations. The study will be performed using a customized model at an early stage of commercial application and have an order value of approximately 0.6 MSEK, of which the majority is expected to impact sales in the second quarter.
The assignment is performed for a returning customer and represents a further step in an ongoing collaboration within non-animal efficacy testing. The order covers a test method that forms part of the SenzaGen Group’s innovation portfolio and confirms commercial interest in VitroScreenORA® as a model for non-animal efficacy testing. The purpose of the project is to evaluate the functionality and moisturizing effects of a medical device product.
“The ORA® platform is an important part of our long-term portfolio. The project supports our continued efforts to further develop and broaden the use of spheroid-based models within relevant biological application areas, in close collaboration with customers,” says Peter Nählstedt, President and CEO of SenzaGen.
VitroScreenORA® is an innovative platform based on cultured human cells designed to mimic real tissue functions. The platform is used in research and development to evaluate efficacy and safety using non-animal methods. In 2025, the subsidiary received an order for a study on a cartilage model, and work continues to further develop and standardize additional models with the ambition of strengthening the platform’s commercial potential.
